Helping patients who have significant medical illness as well as mental illness is a challenge, especially when the diagnosis is unclear. Hospital psychiatrists play a critical role in the management of these behaviorally compromised patients.
We’ve been waiting since 1953, the year chlorpromazine was introduced to the US as a revolutionary treatment for schizophrenia, for an active treatment for tardive dyskinesia that the FDA judged to be effective.
Current research investigates new pathophysiologic mechanisms and lays the groundwork for redefining schizophrenia based on distinct medical subclasses—which may lead to more targeted and effective treatments. Details here.